Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Cigarette smoking continues to cause nearly three in ten cancer deaths in the U.S.

Cigarette smoking continues to cause nearly three in ten cancer deaths in the U.S.

A new American Cancer Society study finds that despite significant drops in smoking rates, cigarettes continue to cause about three in ten cancer deaths in the United States. The study, appearing in the Annals of Epidemiology, concludes that efforts to reduce smoking prevalence as rapidly as possible should be a top priority for the U.S. public health efforts to prevent cancer deaths. [More]
Advances in fight against TB, sudden cardiac death

Advances in fight against TB, sudden cardiac death

Research projects into two of the biggest killers in worldwide health, tuberculosis and sudden cardiac death, will be the subjects of the University of Leicester Graduate School Doctoral Inaugural Lectures, delivered by two of the winners of this year's PhD prizes in the College of Medicine, Biological Sciences and Engineering. [More]
PD-1, PD-L1 differentially expressed in NSCLC

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates. [More]
Agent THZ1 shrinks human-like small cell lung tumors in mice

Agent THZ1 shrinks human-like small cell lung tumors in mice

Small cell lung cancer - a disease for which no new drugs have been approved for many years - has shown itself vulnerable to an agent that disables part of tumor cells' basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported. [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
Nivolumab drug highly effective for Hodgkin's lymphoma

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments. [More]
BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015. [More]
New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy. [More]
CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold. [More]
‘Optimal degree’ of catch-up growth defined for SGA babies

‘Optimal degree’ of catch-up growth defined for SGA babies

A growth trajectory in which small for gestational age babies achieve catch-up growth to a defined degree within the first few months of life appears to be best for their subsequent health, say researchers. [More]
Exome sequencing refines 46,XY DSD diagnosis

Exome sequencing refines 46,XY DSD diagnosis

Exome sequencing can identify a likely genetic cause of 46,XY disorders of sex development in about a third of cases, report researchers. [More]
Closed-loop artificial pancreas system improves diabetes management in adolescents

Closed-loop artificial pancreas system improves diabetes management in adolescents

Research shows that the use of an artificial pancreas system helps to compensate for omission and underestimation of insulin boluses in adolescents with Type 1 diabetes. [More]
Congenital hypothyroidism of central origin often requires treatment

Congenital hypothyroidism of central origin often requires treatment

Congenital hypothyroidism of central origin should not be dismissed as a mild condition and is worth screening for, say researchers. [More]
Inhibin B plus baseline LH levels aids hypogonadotropic hypogonadism diagnosis in boys

Inhibin B plus baseline LH levels aids hypogonadotropic hypogonadism diagnosis in boys

Researchers recommend measuring inhibin B concentration in combination with basal luteinising hormone as a first-line test to discover the underlying cause of delayed puberty in boys. [More]
Philips introduces new lung screening solution at RSNA 2014

Philips introduces new lung screening solution at RSNA 2014

Royal Philips today introduced a new lung screening solution designed to offer health care providers a faster and more definitive pathway to lung cancer detection and treatment. Making its debut at the 2014 Radiological Society of North America Annual Meeting in Chicago this week, this total solution is comprised of products and services that enable health care providers to implement and manage a comprehensive computed tomography (CT) lung screening program which tracks and guides patients across the health continuum. [More]

Medical experts to discuss Saatchi Bill at free public event

The Saatchi Bill claims that it will help doctors to innovate new treatments and cures, safely and responsibly, for cancer and other diseases. [More]
Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine. [More]
Study finds striking gap in cancer survival between countries and regions

Study finds striking gap in cancer survival between countries and regions

The CONCORD-2 study, published in The Lancet, reports 5-year survival estimates for 25·7 million cancer patients diagnosed with one of 10 common cancers and 75 000 children diagnosed with acute lymphoblastic leukaemia between 1995 and 2009, using individual patient data from 279 cancer registries in 67 countries. [More]
Researchers identify key molecule that drives excess protein production in Fragile X patients' brain

Researchers identify key molecule that drives excess protein production in Fragile X patients' brain

People affected by a common inherited form of autism could be helped by a drug that is being tested as a treatment for cancer. [More]